艾拉莫德联合甲氨喋呤治疗类风湿关节炎的效果及对类风湿因子、红细胞沉降率、糖皮质激素受体水平的影响

Therapeutic effect of Elamode combined with methotrexate on rheumatoid arthritis and its influence on RF,ESR and GR levels

目的分析艾拉莫德联合甲氨喋呤治疗类风湿关节炎的效果及对类风湿因子(RF)、红细胞沉降率(ESR)、糖皮质激素受体(GR)水平的影响,以探讨临床治疗该病的最佳方案,促进患者尽早康复。方法选取92例类风湿关节炎患者,根据不同疗法将其纳入对照组与观察组各46例。对照组给予艾拉莫德治疗,观察组给予艾拉莫德联合甲氨喋呤治疗,对比两组患者的临床疗效、症状体征变化(晨僵时间、关节压痛指数、关节肿胀指数)、实验室指标(RF、ESR、GR)以及不良反应(皮疹、口腔溃疡、恶心呕吐、肝功能异常)。结果观察组的总有效率(95. 7%)高于对照组(78. 3%),观察组治疗后的晨僵时间、关节压痛指数、关节肿胀指数[(32. 1±10. 0) min、(16. 8±5. 5)分、(5. 7±1. 3)分]均少于对照组[(76. 9±15. 2) min、(29. 5±8. 3)分、(12. 4±3. 8)分],观察组治疗后的RF、ESR、GR水平[(37. 3±6. 0) IU/mL、(15. 0±3. 8) IU/h、(47. 4±10. 1) nmol/L]均低于对照组[(56. 6±8. 3) IU/mL、(36. 5±5. 4) IU/h、(70. 5±13. 7) nmol/L],P均<0. 05。观察组的不良反应发生率(13. 0%)与对照组(10. 9%)相当,P> 0. 05。结论艾拉莫德联合甲氨喋呤治疗类风湿关节炎的疗效显著,可明显改善患者的症状体征与实验室指标,与单用艾拉莫德治疗相比未新增不良反应。

Objective To analyze the efficacy of Elamode combined with methotrexate in the treatment of rheumatoid arthritis and its influence on the levels of rheumatoid factor( RF),erythrocyte sedimentation rate( ESR),glucocorticoid receptor( GR) in order to explore the best clinical treatment of the disease and promote the early recovery of patients. Methods 92 patients with rheumatoid arthritis were selected. According to different therapies,they were included in the control group and observation group,46 cases in each group. The control group was treated with Elamode,while the observation group was treated with Elamode combined with methotrexate. The clinical efficacy,symptoms and signs( morning stiffness time,joint tenderness index,joint swelling index) of the two groups were compared. Laboratory indicators( RF,ESR,GR) and adverse reactions( rash,oral ulcer,nausea and vomiting,abnormal liver function). Results The total effective rate of the observation group( 95. 7%) was higher than that of the control group( 78. 3%).The morning stiffness time,joint tenderness index,joint swelling index [( 32. 1 ± 10. 0) min,( 16. 8 ± 5. 5) points,( 5. 7± 1. 3) points] of the observation group were lower than those of the control group(( 76. 9 ± 15. 2) min,( 29. 5 ± 8. 3)points,( 12. 4 ± 3. 8) points)The levels of RF,ESR and GR of the observation group[( 37. 3 ± 6. 0) IU/mL,( 15. 0 ±3. 8) IU/h,( 47. 4 ± 10. 1) nmol/L] were lower than those of the control group [( 56. 6 ± 8. 3) IU/mL,( 36. 5 ± 5. 4)IU/h,( 70. 5 ± 13. 7) nmol/L],all P < 0. 05. The incidence of adverse reactions in the observation group( 13. 0%) was similar to that in the control group( 10. 9%),P > 0. 05. Conclusion Elamode combined with methotrexate in the treatment of rheumatoid arthritis is effective,can significantly improve the symptoms and signs of patients and laboratory indicators,compared with the treatment of Elamode alone,no new adverse reactions,it is worthy of clinical implementation.